Mergers & Acquisitions ·
Sanara shareholders approve merger with MiMedx; HSR waiting period resets to October 15
SMTISanara MedTech Inc.
Sanara MedTech Inc. shareholders approved the merger agreement with MiMedx Group, Inc., under which MiMedx will acquire Sanara as a wholly-owned subsidiary. The vote passed with 6,372,989 shares in favor against 1,944 opposed. Additionally, shareholders approved non-binding advisory compensation related to the transaction. Regarding regulatory status, MiMedx voluntarily withdrew and refiled its Hart-Scott-Rodino notification on September 15, 2026, resetting a new 30-day waiting period that expires October 15, 2026. Sanara MedTech Inc. operates in the medical technology industry, specializing in regenerative medicine products derived from human placental tissue.